Kwality Pharmaceuticals, a leading pharmaceutical manufacturing company in India specialising in complex molecules, has announced the successful completion of the European Union Good Manufacturing Practices (EU-GMP) audit at its Amritsar manufacturing facilities, encompassing both the General and Beta-Lactam units. 

In a regulatory filing, the company confirmed that the audit concluded with no major observations, reaffirming its commitment to maintaining the highest international quality and compliance standards.

“This milestone underscores Kwality Pharma’s continuous pursuit of excellence in manufacturing and regulatory adherence,” he company stated.

With this latest achievement, Kwality Pharma now boasts four EU-approved facilities — general, beta-lactam, cephalosporin and oncology — further solidifying its position as a trusted global pharmaceutical manufacturer with a strong presence across multiple therapeutic areas and dosage forms.

The successful completion of the EU-GMP audit not only reinforces the company’s dedication to patient safety, product quality and regulatory compliance but also paves the way for expansion into more regulated international markets. This milestone unlocks new opportunities for sustainable growth and strategic collaborations, the company added.